An Analysis of Demographics and Inhaled Corticosteroid Use on COVID-19 Outcomes Among Hospitalized Adult Asthmatics: An Early Experience at a NY Hospital System

References

• CDC. People with certain medical conditions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Accessed August 19, 2021.
   Google Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–1207. doi:10.1056/NEJMoa2001316
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
   PubMed Web of Science ®Google Scholar
• Docherty AB, Harrison EM, Green CA, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO clinical characterisation protocol. BMJ. 2020;369:m1985. doi:10.1136/bmj.m1985
   PubMed Web of Science ®Google Scholar
• Mendes NF, Jara CP, Mansour E, Araujo E, Velloso LA. Asthma and COVID-19 -A systematic review. Allergy Asthma Clin Immunol. 2021;17(1). doi:10.22541/au.159118771.11841404
   Web of Science ®Google Scholar
• Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan [published online ahead of print April 12, 2020]. J Allergy Clin Immunol. 2020;146:110–118. doi:10.1016/j.jaci.2020.04.006
   PubMed Web of Science ®Google Scholar
• Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146(2):307–314.e4. PMID: 32554082; PMCID: PMC7295471. doi: 10.1016/j.jaci.2020.06.010
   PubMed Web of Science ®Google Scholar
• Singer AJ, Morley EJ, Meyers K, et al. Cohort of 4404 persons under investigation for COVID-19 in a NY hospital and predictors of ICU care and ventilation [published online ahead of print April 23, 2020]. Ann Emerg Med. 2020. doi:10.2139/ssrn.3583678
   Web of Science ®Google Scholar
• Lieberman-Cribbin W, Rapp J, Alpert N, Tuminello S, Taioli E. The impact of asthma on mortality in patients with COVID-19. Chest. 2020;158(6):2290–2291. doi:10.1016/j.chest.2020.05.575
   PubMed Web of Science ®Google Scholar
• Lovinsky-Desir S, Deshpande DR, De A, et al. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol. 2020;146(5):1027–1034.e4. PMID: 32771560; PMCID: PMC7409831. doi: 10.1016/j.jaci.2020.07.026
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. doi:10.1038/s41586-020-2521-4
   PubMed Web of Science ®Google Scholar
• Lee SC, Son KJ, Han CH, Jung JY, Park SC. Impact of comorbid asthma on severity of coronavirus disease (COVID-19). Sci Rep. 2020;10(1):21805. PMID: 33311519; PMCID: PMC7733453. doi:10.1038/s41598-020-77791-8
   PubMed Web of Science ®Google Scholar
• Caminati M, Vultaggio A, Matucci A, et al. Asthma in a large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021;176:106261. PMID: 33260107; PMCID: PMC7688414. doi:10.1016/j.rmed.2020.106261
   PubMed Web of Science ®Google Scholar
• Atkins JL, Masoli JAH, Delgado J, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK biobank community cohort. J Gerontol a Biol Sci Med Sci. 2020;75(11):2224–2230. PMID: 32687551; PMCID: PMC7454409. doi:10.1093/gerona/glaa183
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al.; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8):693–704. PMID: 32678530; PMCID: PMC7383595. doi:10.1056/NEJMoa2021436
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Murthy S, Diaz JV, et al.; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341. PMID: 32876694; PMCID: PMC7489434. doi:10.1001/jama.2020.17023
   PubMed Web of Science ®Google Scholar
• Choi JC, Jung SY, Yoon UA, et al. Inhaled Corticosteroids and COVID-19 risk and mortality: a nationwide cohort study. J Clin Med. 2020;9(11):3406. PMID: 33114246; PMCID: PMC7690894. doi:10.3390/jcm9113406
   PubMed Web of Science ®Google Scholar
• Matsuyama S, Kawase M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells. J Virol. 2020;95(1):e01648–20. PMID: 33055254; PMCID: PMC7737752. doi:10.1128/JVI.01648-20
   PubMed Web of Science ®Google Scholar
• Jeon S, Ko M, Lee J, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819–20. PMID: 32366720; PMCID: PMC7318052. doi:10.1128/AAC.00819-20
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. PMID: 32142651; PMCID: PMC7102627. doi: 10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Busse WW, Bacharier LB, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203–206.e3. PMID: 32333915; PMCID: PMC7175851. doi: 10.1016/j.jaci.2020.04.009
   PubMed Web of Science ®Google Scholar
• Kimura H, Francisco D, Conway M, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020;146(1):80–88.e8. PMID: 32422146; PMCID: PMC7227558. doi: 10.1016/j.jaci.2020.05.004
   PubMed Web of Science ®Google Scholar
• Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma. relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83–90. Erratum in: Am J Respir Crit Care Med. 2020 Dec 15;202(12):1744-1746. PMID: 32348692; PMCID: PMC7328313. doi:10.1164/rccm.202003-0821OC
   PubMed Web of Science ®Google Scholar
• Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. J Allergy Clin Immunol. 2020;146(4):685–693. PMID: 33032723. doi:10.1016/j.jaci.2020.08.011
   PubMed Web of Science ®Google Scholar
• Bloom CI, Saglani S, Feary J, Jarvis D, Quint JK. Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006–2016. Eur Respir J. 2019;53(4):1802130. PMID: 30765507. doi:10.1183/13993003.02130-2018
   PubMed Web of Science ®Google Scholar
• Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92(10):1915–1921. PMID: 32293753; PMCID: PMC7262275. doi: 10.1002/jmv.25889
   PubMed Web of Science ®Google Scholar
• Colombo D, Zagni E, Ferri F, Canonica GW; PROXIMA study centers. Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient reported outcomes and Xolair® in the management of asthma) study. Allergy Asthma Clin Immunol. 2019;15(1):65. PMID: 31708980; PMCID: PMC6833238. doi:10.1186/s13223-019-0380-z
   PubMed Web of Science ®Google Scholar
• Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449–1458. PMID: 32790106; PMCID: PMC7436673. doi: 10.1002/jmv.26424
   PubMed Web of Science ®Google Scholar
• Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29. PMID: 32450906; PMCID: PMC7247289. doi:10.1186/s13293-020-00304-9
   PubMed Web of Science ®Google Scholar
• Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. PMID: 32411652; PMCID: PMC7201103. doi:10.3389/fpubh.2020.00152
   PubMed Web of Science ®Google Scholar
• Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–1329. PMID: 32306492; PMCID: PMC7264730. doi:10.1111/jth.14859
   PubMed Web of Science ®Google Scholar
• Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92(10):2188–2192. PMID: 32436996; PMCID: PMC7280691. doi: 10.1002/jmv.26031
   PubMed Web of Science ®Google Scholar
• Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–1028. PMID: 32286245. doi:10.1515/cclm-2020-0369
   PubMed Web of Science ®Google Scholar
• Maes T, Bracke K, Brusselle GG. COVID-19, asthma, and inhaled corticosteroids: another beneficial effect of inhaled corticosteroids? Am J Respir Crit Care Med. 2020;202(1):8–10. PMID: 32437628; PMCID: PMC7328335. doi:10.1164/rccm.202005-1651ED
   PubMed Web of Science ®Google Scholar
• Simpson JL, Carroll M, Yang IA, et al. Reduced antiviral interferon production in poorly controlled asthma is associated with neutrophilic inflammation and high-dose inhaled corticosteroids. Chest. 2016;149(3):704–713. PMID: 26836898. doi: 10.1016/j.chest.2015.12.018
   PubMed Web of Science ®Google Scholar
• Schultze A, Walker AJ, MacKenna B, et al.; OpenSAFELY Collaborative. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020; 9(11):1106–1120. PMID: 32979987; PMCID: PMC7515601. doi:10.1016/S2213-2600(20)30415-X
   Web of Science ®Google Scholar
• Izquierdo JL, Almonacid C, González Y, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. 2021;57(3):2003142. PMID: 33154029; PMCID: PMC7651839. doi:10.1183/13993003.03142-2020
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a Phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772; Erratum in: Lancet Respir Med. 2021 Jun;9(6):e55.PMID: 33844996; PMCID: PMC8040526. doi: 10.1016/S2213-2600(21)00160-0
   PubMed Web of Science ®Google Scholar
• Yu LM, Bafadhel M, Dorward J, et al.; PRINCIPLE Trial Collaborative Group. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021:S0140–S6736. PMID: 34388395; PMCID: PMC8354567. doi:10.1016/S0140-6736(21)01744-X
   Web of Science ®Google Scholar